InvestorsHub Logo
Followers 14
Posts 306
Boards Moderated 0
Alias Born 01/17/2021

Re: Number sleven post# 368570

Wednesday, 02/02/2022 8:28:06 PM

Wednesday, February 02, 2022 8:28:06 PM

Post# of 426478
NS - what's interesting about Reddy CEO presentation

Erez Israeli: And in terms of supply, it is not constraining us at this stage.



Oh really. The judge in your antitrust lawsuit claiming Amarin bought up all the supply of the API might be interested in your words.


Erez Israeli: There is still a lot of market share to gain with this product as the innovator is still holding a nice market share.

Sameer Baisiwala: Then why is the market share in early double-digit and not much higher if supply is not holding you back? What's the roadblock?


Erez Israeli: The roadblock is the desire of customers to take the product from us.

Sameer Baisiwala: Is anything different over here?

Erez Israeli: No, nothing different here.



Let me help you out here Dr. Reddy. Would you care to acknowledge that your generic is not to be prescribed for cardiovascular risk reduction in this country. Did you just admit that the valid Amarin patents are not viewed as impediments to your market? Kinda sounded like you said you are entitled to the "innovator's" market.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News